First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients

Enfortumab vedotin (EV), an antibody–drug conjugate directed against Nectin-4, significantly prolonged survival compared to standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who previously received platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Vulsteke, Christof, De Cocker, Laurens, Gómez de Liaño, Alfonso, Montesdeoca, Cristina, De Meulenaere, Astrid, Croes, Lieselot, Delombaerde, Danielle, Szabados, Bernadett, Powles, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057070/
https://www.ncbi.nlm.nih.gov/pubmed/36986475
http://dx.doi.org/10.3390/ph16030375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057070/
https://www.ncbi.nlm.nih.gov/pubmed/36986475
http://dx.doi.org/10.3390/ph16030375

Ejemplares similares